Lexitas Pharma Services’ Post

Transcript

I think some of the trends that we're seeing in ophthalmology trials is just looking at novel endpoints for these therapies that we're evaluating. A great example is even in geographic atrophy and how we're looking at function and the real impact to patients and some of those end points that I think we'll see in future clinical trials probably don't even exist yet. And so there's a lot of great research and innovation happening there. And also just the delivery mechanism and durability for products, I think gene therapy, cell therapy. Has a ton of promise and there's a lot of those trials ongoing and have a lot of opportunity for patients as we see those evolve.